Positive Phase III data from Checkmate-577 for adjuvant nivolumab in oesophageal or gastroesophageal junction cancer

In patients who had previously received neoadjuvant chemoradiation and tumour resection, nivolumab was associated with prolonged disease-free survival versus placebo (median 22.4 months versus 11.0 months, respectively; HR 0.69; p=0.0003).

Source:

Business Wire